ACM
BMRN icon

Advent Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Advent Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,520
Closed -$396K – 255
2020
Q4 		$396K Buy
4,520
+520
+13% +$41.2K 0.01% 165
2020
Q3 		$304K Buy
+4,000
New +$405K 0.01% 162
2018
Q4 		– Sell
-8,600
Closed -$834K – 257
2018
Q3 		$834K Buy
+8,600
New +$858K 0.02% 187
2017
Q3 		– Sell
-5,500
Closed -$486K – 297
2017
Q2 		$500K Buy
5,500
+2,860
+108% +$260K 0.01% 207
2017
Q1 		$232K Buy
+2,640
New +$235K ﹤0.01% 209
2016
Q4 		– Sell
-3,450
Closed -$297K – 308
2016
Q3 		$319K Buy
+3,450
New +$325K ﹤0.01% 406
2016
Q2 		– Sell
-4,000
Closed -$340K – 459
2016
Q1 		$330K Buy
4,000
+1,047
+35% +$85.2K 0.01% 341
2015
Q4 		$313K Sell
2,953
-1,704
-37% -$178K ﹤0.01% 370
2015
Q3 		$490K Buy
4,657
+4,055
+674% +$542K 0.01% 401
2015
Q2 		$82K Sell
602
-52,488
-99% -$6.5M ﹤0.01% 442
2015
Q1 		$6.62M Buy
53,090
+44,490
+517% +$4.71M 0.1% 210
2014
Q4 		$777K Sell
8,600
-14,746
-63% -$1.23M 0.01% 389
2014
Q3 		$1.69M Sell
23,346
-355
-1% -$23.3K 0.03% 353
2014
Q2 		$1.66M Buy
+23,701
New +$1.43M 0.02% 350
2013
Q4 		– Sell
-41,261
Closed -$2.98M – 601
2013
Q3 		$2.98M Buy
41,261
+4,261
+12% +$283K 0.04% 339
2013
Q2 		$2.06M Buy
+37,000
New +$2.31M 0.03% 343

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Advent Capital Management's BMRN Position: Q1 2021 in Review

Advent Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 4,520 shares — an estimated $396K sold.

Advent Capital Management first reported a position in BMRN in Q2 2013 and held it in 16 quarters. The position peaked at $6.62M in Q1 2015. 531 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

  • Advent Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Advent Capital Management sold 4,520 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $396K.
  • Advent Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 16 quarters.
  • Advent Capital Management's BioMarin Pharmaceuticals position peaked at $6.62M in Q1 2015.
  • 531 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Advent Capital Management's 13F filing for Q1 2021, filed 17 May 2021.